Path Therapeutics

Path Therapeutics is a small-molecule drug-discovery biotech company whose lead program is centred on a class of severe brain disorders first diagnosed in childhood and defined by aggressive seizures that almost always fail to be controlled by current medications.

Path Therapeutics is active in the prime space.

The company sits in the prime segment, where it competes on its core product or service.

The company is listed at the Creative Destruction Lab alumni company stage of development.

Website: pathbio.com